Abstract: A method for detecting an analyte involving a) contacting the analyte, a capture agent and a solid surface to form a capture complex attached to a solid surface, b) cleaving at least one covalent bond within the analyte and/or within said capture agent in the capture complex and, thereby, releasing the analyte or a fragment thereof from the capture complex, and c) detecting at least one fragment of the analyte and, thereby, detecting the analyte is disclosed herein. A kit having i) a capture agent binding to an analyte; and ii) an agent cleaving at least one covalent bond within the analyte and/or within the capture agent; and to the use of a protease for releasing fragments of an analyte for detecting the analyte, wherein the analyte is bound to a solid surface via a capture agent is also disclosed herein.
Type:
Grant
Filed:
April 19, 2019
Date of Patent:
February 21, 2023
Assignee:
Roche Diagnostics Operations, Inc.
Inventors:
Uwe Kobold, Robert Lang, Andreas Leinenbach
Abstract: The invention relates to an in vitro method for the diagnosis of acute pancreatitis (AP) in a subject by detection of Glycoprotein 2 isoform alpha (GP2a) protein.
Abstract: A method for detecting an analyte according to the present invention includes: a first step of supplying a specimen to a detection device having a first ligand that is immobilized on a substrate and is capable of specifically binding to the analyte, the specimen being supplied onto the substrate of the detection device, and then causing the analyte included in the specimen to bind to the first ligand; a second step of supplying, onto the substrate, a second ligand that is labeled with a marker and is capable of specifically binding to the analyte, and then causing the second ligand to bind to the analyte bound to the first ligand; and a third step of measuring the second ligand bound to the analyte, wherein in the second step, carboxymethyl dextran is supplied onto the substrate.
Abstract: The present invention provides methods for analysing a urine sample from a subject comprising exposing the urine sample to a lysis buffer which is capable of releasing at least one biomarker from cells in the urine sample. The present invention further provides kits, devices, and apparatuses that can be used in these methods. Finally, the present invention provides methods for detecting the presence of a urological cancer in a subject comprising performing an assay on a sample from a subject to determine the concentration of an Mcm protein.
Type:
Grant
Filed:
June 1, 2016
Date of Patent:
December 6, 2022
Assignee:
ARQUER DIAGNOSTICS LIMITED
Inventors:
David Nicholas Miller-Jones, Jacqueline Stockley, Cheryl Nyberg
Abstract: The invention described herein relates to methods of monitoring genotoxic stress in a test subject, specifically by detecting the expression level of microvesicle-associated H2AX from a biological sample.
Abstract: The invention provides methods and systems for detecting a biomarker in a synovial fluid wherein the system also includes a control to ensure that the test sample is indeed synovial fluid. The biomarkers and the control for synovial fluid can be identified using proteomic methods, including but not limited to antibody based methods, such as an enzyme-linked immunosorbant assay (ELISA), a radioimmunoassay (RIA), or a lateral flow immunoassay.
Type:
Grant
Filed:
September 26, 2018
Date of Patent:
November 15, 2022
Assignee:
CD Diagnostics, Inc.
Inventors:
Carl Deirmengian, Richard C. Birkmeyer, Keith Kardos, Patrick Kilmartin, Alexander Cameron, Kevin Schiller, Eun Kyung Chung
Abstract: A method for detecting a substance to be detected, which comprises bringing a) a first recognizing substance bound to a fibrous substance, b) a second recognizing substance which is labeled, and c) a substance to be detected, provided that the first recognizing substance and the second recognizing substance are capable of being bound to the substance to be detected, into contact with one another in a dispersed state so as to form a complex in which the above a, b and c are bound together, separating the complex and an unbound b, and detecting the label of the obtained complex.
Abstract: The present disclosure is directed to a method of identifying a patient having heart failure as likely to respond to a therapy with a statin. The method is based on measuring the level of at least one marker selected from GDF-15 (Growth Differentiation Factor 15), Urea, SHBG (Sex Hormone-Binding Globulin), Uric acid, PLGF (Placental Growth Factor), IL-6 (Interleukin-6), Transferrin, a cardiac Troponin, sFlt-1 (Soluble fms-like tyrosine kinase-1), Prealbumin, Ferritin, Osteopontin, sST2 (soluble ST2), and hsCRP (high sensitivity C-reactive protein) in a sample from a patient. Further envisaged is a method of predicting the risk of a patient to suffer from death or hospitalization, wherein the patient has heart failure and undergoes a therapy with a statin. The method is also based on the measurement of the level of at least one of the aforementioned markers.
Type:
Grant
Filed:
January 25, 2019
Date of Patent:
October 4, 2022
Assignee:
Roche Diagnostics Operations, Inc.
Inventors:
Dirk Block, Hanspeter Brunner, Thomas Dieterle, Ursula-Henrike Wienhues-Thelen, Christian Zaugg, Andre Ziegler
Abstract: Quantitation of specific antibodies for at least one redox form of High mobility group box 1 (HMGB1) contained in a biological sample. An in vitro method for assessing the state of progression of a disease or a disorder in which HMGB1 is involved. An in vitro method for the identification of predisposition, prognostic or diagnostic biomarkers of a disease or a disorder in which HMGB1 is involved. A kit to quantitate said specific antibodies for at least one redox form of HMGB1.
Type:
Grant
Filed:
November 3, 2016
Date of Patent:
October 4, 2022
Assignee:
INSTITUT PASTEUR
Inventors:
Marie-Lise Gougeon, Nicole Prada, Hela Saidi
Abstract: The present invention contemplates use of encapsulated aqueous and non-aqueous reagents, solutions and solvents and their use in laboratory procedures. These encapsulated aqueous or non-aqueous reagents, solutions and solvents can be completely contained or encapsulated in microcapsules or nanocapsules that can be added to an aqueous or non-aqueous carrier solution or liquid required for medical and research laboratory testing of biological or non-biological specimens.
Abstract: Methods for identifying and optionally treating subjects, e.g., subjects who have Chronic Rhinosinusitis (CRS), based on the detection of elevated levels of soluble P-glycoprotein in nasal secretions. The methods of treatment can include administration of a therapeutically effective amount of a P-glycoprotein inhibitor.
Abstract: This document provides methods and materials involved in identifying and treating autoimmune GFAP (glial fibrillary acidic protein) astrocytopathy, a novel meningoencephalomyelitis, in humans as well as methods and materials for identifying and offering early treatment for patients having autoimmune GFAP astrocytopathy whose autoantibody profile predicts a high likelihood of having underlying cancer (e.g., adenocarcinoma or teratoma).
Type:
Grant
Filed:
September 6, 2017
Date of Patent:
August 2, 2022
Assignee:
Mayo Foundation for Medical Education and Research
Inventors:
Vanda A. Lennon, Andrew McKeon, Boyan Fang, Shannon Hinson, Thomas J. Kryzer
Abstract: The present invention relates generally to the field of implant related risk of revision, in particular implant related risk of revision not caused by an infection or metal on metal reaction. The present invention provides methods of diagnosing implant related risk of revision, use of kits for such diagnostic purposes and compositions for use in the treatment of implant related risk of revision, in particular implant related risk of revision not caused by an infection or metal on metal reaction.
Type:
Grant
Filed:
February 7, 2018
Date of Patent:
August 2, 2022
Assignee:
LYFSTONE AS
Inventors:
Stein Lian, Jarle Mikalsen, Eric Bendiksen, Anders Einung Hansen
Abstract: The present invention relates to methods and systems for detecting one or more analytes in a sample and/or for classifying a sample. In particular, the present invention relates to methods and systems which can be used to detect the analytes in real time and which rely on flowing through a microfluidic device one or more types of sensor molecule each comprising a domain that binds one or more analytes, a chemiluminescent donor domain and an acceptor domain, wherein the separation and relative orientation of the chemiluminescent donor domain and the acceptor domain, in the presence and/or the absence of analyte, is within ±50% of the Forster distance.
Type:
Grant
Filed:
September 25, 2019
Date of Patent:
July 12, 2022
Assignee:
Commonwealth Scientific and Industrial Research Organisation
Inventors:
Stephen Charles Trowell, Helen Dacres, Nam Cao Hoai Le, Murat Gel, Yonggang Zhu, Nan Wu
Abstract: An assay device is provided for use in determining the presence of a target analyte in a sample. The assay device comprises a solid platform comprising a fibrous mat, the solid platform impregnated with a first FRET chromophore. An antibody-FRET chromophore conjugate is immobilized on a surface of the solid platform, wherein the antibody-FRET chromophore conjugate comprises an antibody affixed to a second FRET chromophore. The first FRET chromophore and the second FRET chromophore are selected to provide an energy transfer from one to another when located within a Förster distance with respect to each other, thereby forming a FRET donor-acceptor chromophore pair. In a further aspect, a method of detecting a target analyte in a sample is provided. In yet a further aspect, packaging sheet materials and packaging articles employing the assay device under certain conditions are provided.
Abstract: This invention is a functionalized diamond crystal with high dispersibility in high ionic strength solution and/or with specific targeting ability, which comprise a diamond crystal and a fatty acid layer. The fatty acid layer works a surfactant and provides a specific targeting feature for the diamond crystal. The feature of the surfactant makes the diamond crystal being easily dispersed in biological surrounding (e.g., phosphate saline buffer) and the feature of specific targeting ability provides the diamond crystal with specific recognizing specific targets. This invention allows researchers to use diamond crystal as a marker for specific labelling.
Abstract: Disclosed herein are, inter alia, methods and compositions useful for detecting and/or quantifying host cell proteins during the production of a product, e.g., a recombinant protein, e.g., an antibody.